Results 201 to 210 of about 26,674 (238)

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet, The
Juergen Rech, K. Tascilar, M. Hagen, A. Kleyer, B. Manger, Verena Schoenau, A. Hueber, Stefan Kleinert, X. Baraliakos, J. Braun, U. Kiltz, M. Fleck, A. Rubbert-Roth, D. Kofler, F. Behrens, M. Feuchtenberger, M. Zaenker, Reinhard Voll, N. Venhoff, Jens Thiel, Cornelia Glaser, E. Feist, G. Burmester, K. Karberg, J. Strunk, Juan D Cañete, Ladislav Šenolt, M. Filková, E. Naredo, Raquel Largo, G. Krönke, Maria-Antonietta D'Agostino, M. Østergaard, Georg Schett   +33 more
exaly   +2 more sources

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.

Journal of Clinical Oncology, 2023
TPS2680 Background: Patients with myocarditis secondary to treatment with an immune checkpoint inhibitor (ICI) represent a poor prognosis population with a critical unmet clinical need. Data have shown that the rate of major adverse cardiac events (MACE)
K. Reynolds, Daniel A. Zlotoff, M. Mooradian, L. Zubiri, P. Ridker, T. Neilan   +5 more
semanticscholar   +1 more source

Higher Abatacept Exposure Decreases Acute GVHD Risk Without Increasing Adverse Events.

Blood, 2023
In the "ABA2" study, the T-cell costimulation blockade agent, abatacept, was safe and effective in preventing acute graft-versus-host disease (AGVHD) after unrelated-donor hematopoietic cell transplantation (URD HCT), leading to FDA approval.
Takuto Takahashi, M. Al-Kofahi, Mutaz M. Jaber, Brandi Bratrude, K. Betz, Yvonne Suessmuth, A. Yu, D. Neuberg, S. Choi, Jeffrey H Davis, C. Duncan, R. Giller, M. Grimley, Andrew C. Harris, D. Jacobsohn, N. Lalefar, N. Farhadfar, M. Pulsipher, S. Shenoy, A. Petrovič, K. Schultz, G. Yanik, B. Blazar, J. Horan, B. Watkins, A. Langston, M. Qayed, L. Kean   +27 more
semanticscholar   +1 more source

Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD).

Rheumatology
OBJECTIVES This randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD).
Rohit Aggarwal, Nantakarn Pongtarakulpanit, Daniel I. Sullivan, S. Moghadam-Kia, S. Bae, Jesse Wilkerson, D. Saygin, Galina Marder, S. Venuturupalli, P. Dellaripa, S. Danoff, Tracy J Doyle, G. Hunninghake, Joyce S Lee, Aryeh Fischer, Jeremy Falk, Cheilonda Johnson, D. Koontz, Dana P. Ascherman, Chester V. Oddis   +19 more
semanticscholar   +1 more source

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.

Blood
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first FDA-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT).
Leslie S. Kean, Linda J Burns, T. D. Kou, R. Kapikian, K. Lozenski, A. Langston, John T. Horan, B. Watkins, M. Qayed, Brandi Bratrude, K. Betz, Xiao-Ying Tang, Mei-Jie Zhang, Sean E Connolly, M. Polinsky, Brian J Gavin, Andres Gomez-Caminero, Marcelo C. Pasquini   +17 more
semanticscholar   +1 more source

Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study.

Rheumatology
OBJECTIVES To investigate cancer risk in rheumatoid arthritis (RA) patients treated with tocilizumab/sarilumab, abatacept, or rituximab compared with those who received tumour necrosis factor inhibitors (TNFi) and compared with biological disease ...
R. Westermann, R. Cordtz, K. Duch, L. Mellemkjaer, M. Hetland, Bergur Magnussen, Lene Dreyer   +6 more
semanticscholar   +1 more source

Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response.

Clinical and Experimental Rheumatology
OBJECTIVES To describe drug survival, safety and treatment response in sarcoidosis patients treated with abatacept or tofacitinib in routine care.
H. Leffers, Bo Baslund, J. Lindhardsen, S. Krintel, Niels Graudal   +4 more
semanticscholar   +1 more source

Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.

Rheumatology, 2020
OBJECTIVE To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD). METHODS This was an observational, multicentre study of RA-ILD patients treated with at least one dose of ABA.
C. Fernández-Díaz, S. Castañeda, R. Melero-González, F. Ortiz-Sanjuan, A. Juan-Mas, C. Carrasco-Cubero, I. Casafont-Solé, A. Olivé, S. Rodríguez-Muguruza, R. Almodóvar-González, R. Castellanos-Moreira, S. Rodriguez-García, C. Aguilera-Cros, I. Villa, S. Ordóñez-Palau, E. Raya-Alvarez, P. Morales-Garrido, C. Ojeda-García, M. Moreno-Ramos, M. G. Bonilla Hernán, Iñigo Hernández Rodríguez, M. López-Corbeto, J. Andreu, J. R. D. D. Jiménez de Aberasturi, A. Ruibal-Escribano, R. Expósito-Molinero, T. Pérez-Sandoval, Ana María López-Robles, Patricia Carreira-Delgado, N. Mena-Vázquez, A. Urruticoechea-Arana, C. Peralta-Ginés, Luis Arboleya-Rodríguez, F. N. Narváez García, D. Palma-Sánchez, E. Cervantes Pérez, O. Maíz-Alonso, María N Alvarez-Rivas, J. Fernández-Melón, Paloma Vela Casasempere, I. Cabezas‐Rodríguez, Iván Castellvi-Barranco, C. González-Montagut, J. Blanco-madrigal, Natividad Del Val-Del Amo, María C Fito, M. Rodríguez‐Gómez, E. Salgado-Pérez, B. García-Magallón, C. Hidalgo-Calleja, R. López-Sánchez, Sabela Fernández-Aguado, J. Fernández-López, S. Castro-Oreiro, I. Serrano-García, A. García-Valle, S. Romero-Yuste, L. Expósito-Pérez, Lorena Pérez-Albadalejo, Á. García-Aparicio, Neus Quillis-Marti, J. A. Bernal-Vidal, Javier Loricera-García, J. Hernández, M. González-Gay, R. Blanco   +65 more
semanticscholar   +1 more source

Abatacept

Reactions Weekly, 2018
  +7 more sources

Abatacept

Reactions Weekly, 2014
  +6 more sources